X4 Pharmaceuticals (XFOR) Change in Account Payables (2017 - 2025)
X4 Pharmaceuticals' (XFOR) quarterly Change in Account Payables came in at $642000.0 in Q4 2025, up 723.08% YoY from $78000.0 in Q4 2024, and up 124.19% on a QoQ basis from -$2.7 million in Q3 2025.
X4 Pharmaceuticals (XFOR) Change in Account Payables (2017 - 2025) Analysis & Trends
X4 Pharmaceuticals (XFOR) has 9 years of Change in Account Payables data on file, last reported at $642000.0 in Q4 2025.
- Quarterly Change in Account Payables rose 723.08% year-over-year to $642000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$3.0 million (down 941.61% YoY) and the FY2025 annual result came in at -$3.0 million, down 941.61% from the prior year.
- Change in Account Payables rose to $642000.0 in Q4 2025, from -$2.7 million in the prior quarter.
- In the past five years, Change in Account Payables ranged from a high of $3.9 million in Q4 2022 to a low of -$3.4 million in Q2 2025.
- A 5-year average of $128000.0 and a median of $41000.0 in 2024 frame the typical range for Change in Account Payables.
- Annual changes were most pronounced in 2022 — Change in Account Payables plunged 3000.0% — and 2025, when it soared 61800.0%.
- Tracing XFOR's Change in Account Payables over 5 years: stood at $1.9 million in 2021, then surged by 109.89% to $3.9 million in 2022, then slumped by 79.31% to $808000.0 in 2023, then plunged by 90.35% to $78000.0 in 2024, then soared by 723.08% to $642000.0 in 2025.
- The last three Change in Account Payables figures came in at $642000.0 (Q4 2025), -$2.7 million (Q3 2025), and -$3.4 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -66.70 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 5.03 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 37.53 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 520,137.79 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | X4 Pharmaceuticals | 533.17 Mn | 338.08 Mn | 7.19 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 642,000.00 |
| Dec 31, 2025 | 642,000.00 |
| Sep 30, 2025 | -2.65 Mn |
| Sep 30, 2025 | -2.65 Mn |
| Jun 30, 2025 | -3.44 Mn |
| Jun 30, 2025 | -3.44 Mn |
| Mar 31, 2025 | 2.48 Mn |
| Mar 31, 2025 | 2.48 Mn |
| Dec 31, 2024 | 78,000.00 |
| Dec 31, 2024 | 78,000.00 |
| Sep 30, 2024 | 580,000.00 |
| Sep 30, 2024 | 580,000.00 |
| Jun 30, 2024 | -948,000.00 |
| Jun 30, 2024 | -948,000.00 |
| Mar 31, 2024 | 4,000.00 |
| Mar 31, 2024 | 4,000.00 |
| Dec 31, 2023 | 808,000.00 |
| Dec 31, 2023 | 808,000.00 |
| Sep 30, 2023 | 3.24 Mn |
| Sep 30, 2023 | 3.24 Mn |